Back to News
Market Impact: 0.35
Tiziana's Intranasal Foralumab Meets Primary Endpoints In Phase 2a Multiple Sclerosis Trial
Source: Nasdaq
Healthcare & Biotech
Tiziana Life Sciences reported positive topline results from its Phase 2a INFORM-MS study: intranasal foralumab met both primary endpoints in patients with non-active secondary progressive multiple sclerosis (na-SPMS). The provided article text contains no numerical efficacy data or further study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
TLSA0.75
More News
- Midterm elections could jolt stocks if Democrats sweep Congress
- Bayer Raises Profit Outlook Helped by Strong Demand for Drugs
- Madrigal Pharma stock soars 10% on profit beat, strong Rezdiffra sales
- Pfizer earnings analysis: questions answered and next catalysts
- Vertex Pharmaceuticals earnings analysis: questions answered and next catalysts
- BioMérieux shares rise 4% as Q3 organic sales beat forecasts